Valuation: Sangamo Therapeutics, Inc.

Market Cap 45.65M 40.58M 37.61M 34.22M 64.58M 4.33B 65.61M 452M 177M 2.26B 171M 168M 7.21B P/E 2024
-2.1x
P/E 2025 -0.96x
Enterprise Value 51.5M 45.78M 42.43M 38.61M 72.85M 4.89B 74.02M 510M 200M 2.55B 193M 189M 8.13B EV / Sales 2024
3.49x
EV / Sales 2025 3.72x
Free-Float
99.07%
Yield 2024 *
-
Yield 2025 -
1 day-21.79%
1 week-25.43%
Current month-25.03%
1 month-23.95%
3 months+69.54%
6 months-57.94%
Current year-73.76%
1 week 0.01
Extreme 0.01
0.15
1 month 0.01
Extreme 0.01
0.16
Current year 0.01
Extreme 0.01
0.6
1 year 0.01
Extreme 0.01
0.69
3 years 0.01
Extreme 0.01
3.18
5 years 0.01
Extreme 0.01
11.49
10 years 0.01
Extreme 0.01
27.5
Manager TitleAgeSince
Chief Executive Officer 63 2016-05-31
Director of Finance/CFO 47 2026-02-02
Chief Tech/Sci/R&D Officer - 2023-05-28
Director TitleAgeSince
Chairman 70 2017-05-31
Director/Board Member 63 2016-05-31
Director/Board Member 68 2016-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
5/25/26 Tax

General Counsel

-4,036 0.0010%
5/25/26 Tax

Executive/Senior Manager

-4,036 0.0010%
5/25/26 Tax

Chief Executive Officer

-12,613 0.0030%
Change 5-day change 1-year change 3-year change Capi.($)
-21.79%-25.43%-82.76%-79.44% 45.65M
-6.60%-8.56%+49.38%+64.90% 65B
+0.26%+5.30%+9.29%+76.73% 51.2B
+0.44%-0.33%+0.11%+62.11% 51.19B
-1.53%+2.70%+30.48%+41.25% 43.93B
-1.34%+4.12%+16.64%+120.28% 41.96B
-5.97%-6.22%+228.95%+483.48% 38.14B
+6.53%+8.02%+16.40%+56.32% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
-0.80%-0.28%+24.84%+24.87% 22.5B
Average -3.17%-2.86%+33.04%+85.23% 37.24B
Weighted average by Cap. -1.53%-0.50%+44.29%+104.99%

Financials

2024 2025
Net sales 57.8M 51.38M 47.62M 43.33M 81.76M 5.49B 83.07M 572M 224M 2.86B 217M 212M 9.13B 39.55M 35.16M 32.59M 29.65M 55.95M 3.75B 56.84M 392M 154M 1.96B 148M 145M 6.24B
Net income -97.94M -87.06M -80.69M -73.42M -139M -9.3B -141M -970M -380M -4.85B -368M -360M -15.46B -123M -109M -101M -92.15M -174M -11.67B -177M -1.22B -477M -6.09B -461M -452M -19.41B
Net Debt -11.35M -10.09M -9.35M -8.51M -16.06M -1.08B -16.32M -112M -44.08M -562M -42.6M -41.7M -1.79B 5.85M 5.2M 4.82M 4.38M 8.27M 555M 8.4M 57.91M 22.7M 290M 21.94M 21.48M 923M
Projected Income Statement - Annual - Sangamo Therapeutics, Inc.
Logo Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. is a genomic medicine company that pioneered the development of zinc finger and capsid delivery technologies to address serious neurological and rare diseases. The Company's assets include clinical-stage programs ST-503 for chronic neuropathic pain and giroctocogene fitelparvovec for hemophilia A, as well as its cell therapy and regulatory T cell (T-Reg) assets. The Company is developing ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. ST-503 uses an AAV vector carrying an engineered zinc finger repressor (ZFR) to specifically target the human gene, SCN9A, that encodes the Nav1.7 sodium channel and is critical for pain signaling. Giroctocogene fitelparvovec is a liver-tropic rAAV6 vector carrying a B-domain deleted F8 gene that is delivered through a single IV infusion. The Company is operating under court supervision in Chapter 11.
Employees
142
Date Price Change Volume
26-10-16 US$0.1102 -21.79% 1,967,535
26-10-15 US$0.1409 +0.71% 3,569,256
26-10-14 US$0.1399 -0.14% 3,471,665
26-10-13 US$0.1401 -6.60% 818,448
26-10-12 US$0.1500 +1.50% 1,059,984
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Sangamo Therapeutics, Inc.

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Sangamo Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SGMOQ Stock